Paolo Tarantnio, 2025 Yvonne’s “Top Voice” Award Winner, Research Fellow at Dana-Farber Cancer Institute, Visiting Professor presso McGill University, shared a post on X:
“HER2DX analysis of the respect trial (adjuvant trastuzumab +/- chemo for elderly pts with HER2+ eBC), published in Nature Communications. The HER2DX risk score was prognostic and the PCR score appeared to identify patients benefitting from chemoterapy. Congrats Kazuki Nozawa!”
Title: HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy
Authors: Kazuki Nozawa, Masataka Sawaki, Yukari Uemura, Michiko Tsuneizumi, Toshimi Takano, Naomi Gondo, Fumikata Hara, Michiko Harao, Tatsuya Toyama, Naruto Taira, Ana Vivancos, Charles M. Perou, Esther Sanfeliu, Fara Brasó-Maristany, Joel S. Parker, Wesley Buckingham, Laia Paré, Guillermo Villacampa, Mercedes Marín-Aguilera, Patricia Villagrasa, Aleix Prat, Hiroji Iwata
Read the full article on Nature Communications.
More posts featuring Paolo Tarantino on OncoDaily.
You Can Also Read: Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment
